Blog
RSS FeedPosted by Michael Wonder on 15 Sep 2023
Company led submission pilot for early evaluation of non-cancer drugs
13 September 2023 - ACE is conducting a pilot of the company-led submission process for selected non-cancer drugs expecting regulatory approval ...
Posted by Michael Wonder on 23 Nov 2022
InnoCare announces approval of Hibruka (orelabrutinib) for the treatment of mantle cell lymphoma in Singapore
22 November 2022 - InnoCare Pharma announced today that Hibruka (orelabrutinib) has been approved by the Health Sciences Authority of Singapore ...
Posted by Michael Wonder on 01 Sep 2022
ACE publishes another tranche of technology guidances (August 2022)
31 August 2022 - Six technology guidance documents were published yesterday. ...
Posted by Michael Wonder on 01 Apr 2022
ACE releases latest trance of drug guidances (April 2022)
1 April 2022 - The Agency for Clinical Effectiveness has released another batch of drug guidances. ...
Posted by Michael Wonder on 25 Mar 2022
Updated procedures and guidelines for company submissions to ACE
25 March 2022 - Version 1.1 of ACE's "Procedures and guidelines for company submissions to the Agency for Care Effectiveness for ...
Posted by Michael Wonder on 03 Mar 2022
Antengene announces Xpovio regulatory approval in Singapore for the treatment of relapsed and/or refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma in three indications
1 March 2022 - First and only in a unique class of XPO1 inhibitors to be approved in Singapore. ...
Posted by Michael Wonder on 14 Feb 2022
Singapore is the latest country to approve Novavax’s COVID vaccine while the U.S. reviews application
14 February 2022 - On Monday, Singapore approved the COVID vaccine from U.S. vaccine maker Novavax for adults over age 18, ...
Posted by Michael Wonder on 07 Feb 2022
Everest Medicines announces first drug approval of Trodelvy in Singapore for second-line metastatic triple negative breast cancer
6 February 2022 - Singapore Health Sciences Authority approval marks the first in a series of expected approvals of Trodelvy ...
Posted by Michael Wonder on 07 Sep 2021
Singapore's health care system: key features, challenges, and shifts
2 September 2021 - Since Singapore became an independent nation in 1965, the development of its health care system has been ...
Posted by Michael Wonder on 04 Feb 2021
Singapore approves Moderna's COVID-19 vaccine: side effects of jab similar to Pfizer's
3 February 2021 - Side effects for the newly approved Moderna COVID-19 vaccine are similar to those reported about the ...
Posted by Michael Wonder on 08 Sep 2020
Singapore's Agency for Care Effectiveness publishes another tranche of drug guidances
1 September 2020 - Plain English summaries are also available. ...
Posted by Michael Wonder on 24 Jun 2020
Towards greater impact in health technology assessment: horizon scanning for new and emerging technologies in Singapore
22 June 2020 - To alert policy makers early about emerging health technologies that could significantly impact the healthcare system at ...
Posted by Michael Wonder on 26 May 2020
Superb health care at ultra low prices? How Singapore does it
26 May 2020 - Can you imagine the United States having a health care system that delivers better outcomes than those ...
Posted by Michael Wonder on 03 Dec 2019
Health technology assessment and its use in drug policies: Singapore
2 December 2019 - Singapore has a robust health care system that is well known for delivering good health outcomes. ...
Posted by Michael Wonder on 03 Dec 2019
Puma Biotechnology licensing partner Specialised Therapeutics receives marketing approval in Singapore for Nerlynx (neratinib) for extended adjuvant treatment of early stage hormone receptor positive HER2-positive breast cancer
2 December 2019 - Puma Biotechnology announced that its licensing partner Specialised Therapeutics Asia has received marketing approval of Nerlynx (neratinib) ...